iBio Secures Nasdaq Listing, Eyes Future Growth iBio, Inc. has received approval to list its stock on the Nasdaq Capital Market, transitioning from NYSE American. Trading under the same ticker "IBIO" begins March 4, 2025. This move aims to enhance stock visibility, improve liquidity, and attract institutional investors, aligning with the company’s innovative biotech focus.123